Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika

Urgent need to redefine pharma companies’ role on several issues of the industry: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth

Health Minister Mandaviya inaugurates the phase II of Mass Drug Administration initiative for Lymphatic Filariasis

India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive

Artificial intelligence facilitates low-cost drug repurposing, says GlobalData

The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.

Godrej reveals how to win the war against Malaria through strategic collaboration

~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership

Mandaviya calls for collaboration to eliminate vector borne diseases

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.

Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland

The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland

CCMB develops India’s first mRNA vaccine technology

The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere